Literature DB >> 15769275

The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.

Raymond L Barnhill1, Jason Katzen, Alain Spatz, Judith Fine, Marianne Berwick.   

Abstract

BACKGROUND: Tumor ulceration (TU) is considered the second most important prognostic factor after Breslow thickness for localized cutaneous malignant melanoma (CMM). However, many studies have not included mitotic rate (MR) with TU in these analyses. When both TU and MR are included in the same analysis, MR appears to be the more important than TU and TU loses its significance as an independent prognostic factor.
METHODS: The relative importance of TU and MR as prognostic factors in localized CMM were compared in a population-based series of 650 consecutive invasive CMM cases ascertained from the Connecticut tumor registry and reviewed by a single dermatopathologist (RLB), during the period between January 15, 1987 and May 15, 1989. Seventeen clinical and histopathological variables including tumor thickness measured in mm, TU recorded as present or absent, and MR recorded as number per mm(2) were included in an unconditional logistic regression model and selected for inclusion using a backward stepwise algorithm with death as an endpoint or at least five-years follow-up.
RESULTS: In the multivariate regression, the independent prognostic factors included: 1. tumor thickness in millimeters (OR = 1.5, 95% CI = 1.3-1.9) 2. moderate mitotic index (between 1 and 6): (OR = 8.3, 95% CI 2.4-28.7), 3. mitotic index (>6): (OR = 11.6, 95% CI = 3.0-44.6), 4. solar elastosis: (inversely associated with mortality)(OR = 0.4, 95% CI = 0.2-8). After adjustment for MR, TU lost its significance. When MR was left out of the analysis, ulceration then became an independent prognostic factor. The model with ulceration only (excluding MR) showed a relative risk (RR) of 2.4 (95%CI: 1.1-5.1). In the model with MR only, MR had a RR of 14.5 (95% CI3.9-53.7). Finally, regression analysis including both TU and MR yielded an RR of 11.6 for MR and 1.7 for TU.
CONCLUSIONS: Our results suggest that MR as a proxy for tumor proliferation is a more important prognostic factor than TU.

Entities:  

Mesh:

Year:  2005        PMID: 15769275     DOI: 10.1111/j.0303-6987.2005.00310.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  19 in total

1.  Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Authors:  John F Thompson; Seng-Jaw Soong; Charles M Balch; Jeffrey E Gershenwald; Shouluan Ding; Daniel G Coit; Keith T Flaherty; Phyllis A Gimotty; Timothy Johnson; Marcella M Johnson; Stanley P Leong; Merrick I Ross; David R Byrd; Natale Cascinelli; Alistair J Cochran; Alexander M Eggermont; Kelly M McMasters; Martin C Mihm; Donald L Morton; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.

Authors:  Chelsea Isom; Lee Wheless; Mary A Hooks; Rondi M Kauffmann
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

4.  Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Authors:  Christopher S Hale; Meng Qian; Michelle W Ma; Patrick Scanlon; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Yongzhao Shao; David Polsky; Iman Osman; Farbod Darvishian
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

Review 5.  Staging and prognosis of cutaneous melanoma.

Authors:  Paxton V Dickson; Jeffrey E Gershenwald
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

6.  [Mitosis in early invasive malignant melanoma. How reliable is histogenetic classification at stage pT1?].

Authors:  H Bösmüller; S Haitchi-Petnehazy; T Hintringer; T Mentzel
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

7.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

8.  Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Authors:  Rita G Ladstein; Ingeborg M Bachmann; Oddbjørn Straume; Lars A Akslen
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

9.  Immunohistochemical expression of hormone receptors in melanoma of pregnant women, nonpregnant women, and men.

Authors:  Jane H Zhou; Kevin B Kim; Jeffrey N Myers; Patricia S Fox; Jing Ning; Roland L Bassett; Hassan Hasanein; Victor G Prieto
Journal:  Am J Dermatopathol       Date:  2014-01       Impact factor: 1.533

10.  Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm).

Authors:  Melanie A Warycha; Jan Zakrzewski; Quanhong Ni; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Iman Osman
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.